Clinical Trial Update: Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Triheptanoin (UX007) for Glucose Transporter Type 1 Deficiency Syndrome has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glucose Transporter Type Deficiency Syndrome

Drugs mentioned

• Triheptanoin (triheptanoin)

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | Phase 2 | Status: COMPLETED | Results posted: 2020-05-29